New Biomarkers Useful in the Treatment of Bipolar Disorder Explored

 

  • The study, which has reviewed more than 40 investigations and 3,000 clinical cases, evaluates new therapeutic follow-up methods to improve the quality of life of these patients.
  • Professionals from IBIMA Plataforma BIONAND, the University of Malaga (UMA) and the Regional University Hospital of Malaga have participated.

 

A team of researchers from the Biomedical Research Institute of Malaga and Nanomedicine Platform (IBIMA Plataforma BIONAND), the University of Malaga (UMA) and the Regional University Hospital of Malaga has conducted a systematic review on the therapeutic value of inflammatory and neurotrophic biomarkers in bipolar disorder.

This study, published in the scientific journal 'Progress in Neuropsychopharmacology & Biological Psychiatry’The study aims to identify new useful biomarkers for the role of immunological factors in the treatment and prognosis of bipolar disorder, a disease that affects between 2 and 3 percent of the world's population.

Bipolar disorder is a mental illness that causes marked abrupt changes in the mood of the person, which sometimes interfere directly in the daily life of patients, alternating phases of depression with mania or hypomania. In this sense, patients go through periods in which they feel low in energy, sadness or negative thoughts that prevent them from concentrating, with other episodes of exaggeratedly high spirits, feelings of euphoria, excess energy or irritability.

Currently, bipolar disorder cannot be cured, but it can be controlled thanks to a combination of medication and psychological therapy, and early detection and treatment are key to improving the quality of life of these patients.

El estudio revisó 40 investigaciones que incluyeron a 3.371 pacientes con diagnóstico de trastorno bipolar, abarcando intervenciones farmacológicas que van desde estabilizadores del ánimo, antipsicóticos y antidepresivos. Los resultados mostraron que algunos biomarcadores dependientes del sistema inmunológico son útiles para el seguimiento de esta enfermedad. Concretamente, los niveles de citocinas inflamatorias, como el TNF-α y la IL-6, juegan un papel importante en la respuesta al tratamiento, aunque los efectos de las diferentes terapias son variables.


The researcher belonging to the 'Neuropsychopharmacology' group of IBIMA Plataforma BIONAND and the Clinical Mental Health Unit of the Regional University Hospital of Malaga, Paloma Ruiz, stressed that this study reinforces the idea that inflammation plays a fundamental role in bipolar disorder, although she recalled that “much remains to be discovered, although we are talking about biomarkers that could help us to personalize treatments in the future, thus improving the quality of life of patients”.

For his part, the co-investigator of this research group at the Institute, Juan Suárez, also an author of this review, emphasizes the therapeutic potential of these findings, since in the words of the scientist himself “by identifying these biomarkers, we are moving towards a more precise and effective medicine, which could transform the clinical management of patients with bipolar disorder, reducing the variability in responses to conventional treatments”.

Finally, the researcher in charge of the Institute's Neuropsychopharmacology group, attached to the Neurosciences Clinical Unit of the Hospital Regional Universitario de Málaga, Fernando Rodríguez de Fonseca, pointed out that “although this was a very important review with a large number of patients and several studies involved, it is on our roadmap to continue exploring the possibilities of these biomarkers in the immediate future”.

            

Study reference:

Ruiz-Sastre P, Gómez-Sánchez-Lafuente C, Martín-Martín J, Herrera-Imbroda J, Mayoral-Cleries F, Santos-Amaya I, Rodríguez de Fonseca F, Guzmán-Parra J, Rivera P, Suárez J. Pharmacotherapeutic value of inflammatory and neurotrophic biomarkers in bipolar disorder: A systematic review. Prog Neuropsychopharmacol Biol Psychiatry. 2024 Aug 30;134:111056. doi: 10.1016/j.pnpbp.2024.111056. Epub 2024 Jun 13. PMID: 38879067.

 

 

Raúl J. Andrade Bellido, es Investigador Responsable del grupo consolidado ‘Hepatogastroenterología, Farmacología y Terapéutica Clínica Traslacional’ de IBIMA Plataforma BIONAND, Catedrático y Director del Departamento de Medicina en la Facultad de Medicina de la Universidad de Málaga, Jefe de Servicio Aparato Digestivo del Hospital Universitario Virgen de la Victoria en Málaga. Además,  es el Responsable del Grupo Español de Hepatopatias asociadas a medicamentos (Spanish DILI Registry), el Coordinador de la Red Ibero-Americana de Hepatopatías asociadas a medicamentos (SLATINDILI) y también del Registro europeo de Hepatopatías asociadas a Medicamentos (Pro-Euro DILI Registry). Chair de la COST Action CA17112 – Prospective European Drug-Induced Liver Injury Network (PRO-EURO DILI NET) y del EASL DHILI Consortium. Horizonte2020. Framework Programme (European Union).